Events

  • Susavion presents at the BioInvestor Forum, October 2018, in San Francisco.
  • Susavion presents at the BIO International Convention, June 2018, in Boston.
  • Susavion presents at the Biotech Showcase, January 2018, in San Francisco.
  • Susavion presents at the BIO International Convention, June 2017, in San Diego
  • Susavion presents at the Biotech Showcase, January 2017, in San Francisco.
  • Susavion presents at the BIO International Convention, June 2016, in San Francisco.
  • Susavion demonstrates in vivo efficacy of svL4 in spontaneously occurring canine tumors. T regulatory cells were dramatically decreased in the microtumor environment
  • The European Patent Office issues to Susavion two patents, Nos. 7,869,233.2 and 7,871,699
  • Susavion presents at the Biotech Showcase, January 2016 in San Francisco
  • Susavion presents at the Life Sciences Summit, December 2015, in New York
  • Susavion demonstrates in vivo efficacy of sv6D in mouse model of late stage ovarian cancer
  • Susavion presents at the BioInvestor Forum, October 2015, in San Francisco
  • Susavion presents at Life Science Nation’s “RESI 4″  2015 in San Francisco January 13
  • Susavion Biosciences, Inc. Selected to Present at Cavendish Global Health Impact Forum
  • The US Patent Office issues to Susavion a new Patent, No. 8,496,942
  • Susavion successfully demonstrates the effectiveness of it’s lead compound, svL4, which stimulates the activation of CD8 T cells and maturation of macrophages, dendritic and NK cells
  • The US Patent Office issues to Susavion a new patent, No. 8,440,697
  • Susavion initiates canine oncology study program for it’s lead compound svL4
  • Susavion presents at Biotech Showcase in San Francisco, January 2015

Publications (peptide mimetics)

  • Eggink LL, Roby KF, Cote R, Hoober JK.  2018. An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides.  Journal for ImmunoTherapy of Cancer 6:28.  https://rdcu.be/LQZV or https://doi.org/10.1186/s40425-018-0339-5
  • Cote R, Eggink LL, Hoober JK.  2017. CLEC receptors, endoctosis and calcium signaling.  AIMS Allergy and Immunology 1(4): 207-231.  https://doi10.3934/Allergy.2017.4.207
  • Roby KF, Eggink LL, Hoober JK. 2017. An innovative immunotherapeutic strategy for ovarian cancer: Glycomimetic peptides [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting, Washington DC
  • Eggink LL, Spyroulias GA, Jones NG, Hanson CV, Hoober JK. 2015. A peptide mimetic of 5-acetylneuraminic acid-galasctose binds with high avidity to siglecs and NKG2D. PLoS ONE 10(6): 1-20.  https://doi.org/10.1371/journal.pone.0130532
  • Kushchayev SV, Eggink LL, Hoober JK, et al.  2012. Monocyte galactose/N-acetylgalactosamine-specific C-type lectin receptor stimulant immunotherapy of an experimental glioma. Part II: combination with external radiation improves survival.  Cancer Management and Research 4: 325–334.   https://doi.org/10.2147/CMAR.S33355
  • Kushchayev SV, Eggink LL, Hoober JK, et al. 2012. Monocyte galactose/N-acetylgalactosamine-specific C-type lectin receptor stimulant immunotherapy of an experimental glioma. Part 1: stimulatory effects on blood monocytes and monocyte-derived cells of the brain. Cancer Management and Research 4 309–323.   https://doi.org/10.2147/CMAR.S33248
  • Eggink LL, Salas M, Hanson CV, and Hoober JK. 2010.  Peptide sugar mimetics prevent HIV Type 1 replication in peripheral blood mononuclear cells in the presence of HIV-positive antiserum. AIDS Research and Human Retroviruses 26: 149-160.   https://doi.org/10.1089/aid.2009.0155
  • Eggink LL, and Hoober JK. 2010, Peptide mimetics of terminal sugars of complex glycans. Glycobiology Insights 2: 63-74. (http://www.la-press.com/peptide-mimetics-of-terminal-sugars-of-complex-glycans-a1866)
  • Eggink LL, and Hoober JK.  2009. A biologically active peptide mimetic of N-acetylgalactosamine/galactose. BMC Research Notes 2: 23. (http://www.biomedcentral.com/1756-0500/2/23)